Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A recent study suggests that women and older adults who use the weight-loss drug ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...